Megan Drill focuses her practice in the areas of executive compensation, equity compensation and employee benefits for public and private companies, with an emphasis on mergers and acquisitions and public offerings.
Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering.
Veritone Announces Sale of Veritone One to Insignia for up to $104 Million
October 22, 2024
Cooley advised Veritone, a company building human-centered enterprise artificial intelligence (AI) solutions, on the sale of its media agency, Veritone One, to Insignia Capital Group.
Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering.
Zhejiang Taimei Medical Technology Announces HK$335.1 Million IPO
October 8, 2024
Cooley advised the underwriters of Zhejiang Taimei Medical Technology (Taimei), a digital solution provider focused on the pharmaceutical and medical device industry in China, on its HK$335.1 million initial public offering.
Cooley advised Confluent, a data-streaming platform pioneering a fundamentally new category of data infrastructure that sets data in motion, on its acquisition of WarpStream, an Apache Kafka-compatible data-streaming platform.
